Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Nifedipine CR (Xin Ran) vs Adalat in Essential Hypertension
NCT02357615Phase 4Unknown
- Sponsor
- Shanghai Shyndec Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nifedipine in essential hypertension (2 arms), sponsored by Shanghai Shyndec Pharmaceutical. Primary endpoint: Change in the average of early morning blood pressure mean systolic and diastolic pressure from baseline at 8 weeks. Status: unknown.
02
Drugs
nifedipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02357615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357615.